Tempest Therapeutics, Inc.TPST
What Tempest Therapeutics, Inc. does.
We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells (“CAR-T”) product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen (“BCMA”) CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma (“rrMM”).
Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma (“HCC”). Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis (“FAP”), with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute (“NCI”) and conducted through the Cancer Prevention Clinical Trials Network (“CP-CTNet”), enabling advancement with limited internal capital deployment.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$19.2M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Free cash flow | -$19.1M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M |
More on TPST.
- Tempest Therapeutics, Inc. summary
- Tempest Therapeutics, Inc. financial statements
- Tempest Therapeutics, Inc. key metrics
- Tempest Therapeutics, Inc. health scores and style box
- Tempest Therapeutics, Inc. earnings
- Tempest Therapeutics, Inc. dividends
- Tempest Therapeutics, Inc. valuation
- Tempest Therapeutics, Inc. ownership and insiders
- Tempest Therapeutics, Inc. peers
Figures from Tempest Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.